{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:33:04Z","timestamp":1769056384817,"version":"3.49.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.disamonth.2022.101352","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T18:15:55Z","timestamp":1648145755000},"page":"101352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Advancement in therapeutic strategies for immune-mediated oral diseases"],"prefix":"10.1016","volume":"69","author":[{"given":"Shankargouda","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazia","family":"mustaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadish","family":"Hosmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafar Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep Kumar","family":"Yadalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeeshan Heera","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Bhandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran Habib","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.disamonth.2022.101352_bib0001","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1096\/fasebj.12.13.1255","article-title":"Molecular mimicry and immune-mediated diseases","volume":"12","author":"Oldstone","year":"1998","journal-title":"FASEB J"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101352_bib0002","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1177\/0022034515605270","article-title":"Osteopontin in immune-mediated diseases","volume":"94","author":"Rittling","year":"2015","journal-title":"J Dent Res"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0003","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.06.012","article-title":"Bystander activation and autoimmunity","volume":"103","author":"Pacheco","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.disamonth.2022.101352_bib0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0300-483X(02)00256-1","article-title":"Environmental chemicals and autoimmune disease: cause and effect","volume":"181-182","author":"Hess","year":"2002","journal-title":"Toxicology"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0006","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5152\/eurjrheum.2019.18184","article-title":"Effects of childhood psychological trauma on rheumatic diseases","volume":"6","author":"Salihoglu","year":"2019","journal-title":"Eur J Rheumatol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101352_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","article-title":"The World Incidence and Prevalence of Autoimmune Diseases is Increasing","volume":"3","author":"Lerner","year":"2016","journal-title":"Int J Celiac Dis"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101352_bib0008","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0030297","article-title":"A Proposed Classification of the Immunological Diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0009","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ijd.12681","article-title":"Immune-mediated diseases: what can be found in the oral cavity?","volume":"54","author":"Bascones-Mart\u00ednez","year":"2015","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0010","first-page":"9","article-title":"Oral manifestations of autoinflammatory and autoimmune diseases","volume":"27","author":"Baglama","year":"2018","journal-title":"Acta dermatovenerologica Alpina, Pannonica, Adriat"},{"key":"10.1016\/j.disamonth.2022.101352_bib0011","first-page":"11","article-title":"Oral dysbiosis and autoimmunity: from local periodontal responses to an imbalanced systemic immunity. a review","author":"Su\u00e1rez","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2021.100634","article-title":"Does periodontitis play a causal role in the Systemic lupus erythematosus? A systematic review","author":"Allaf","year":"2021","journal-title":"Informatics Med Unlocked"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0013","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/eji.201948322","article-title":"The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention","volume":"50","author":"Fitzgibbon","year":"2020","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cei.13158","article-title":"The microbiome in autoimmune diseases","volume":"195","author":"De Luca","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/6061825","article-title":"Autoimmune diseases and their manifestations on oral cavity: diagnosis and clinical management","volume":"2018","author":"Saccucci","year":"2018","journal-title":"J Immunol Res"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101352_bib0016","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.autrev.2015.06.005","article-title":"Oral mucosal manifestations of autoimmune skin diseases","volume":"14","author":"Mustafa","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0017","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical Pharmacology of Corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respir Care"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101352_bib0018","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/odi.12634","article-title":"Interventions for the management of oral lichen planus: a review of the conventional and novel therapies","volume":"23","author":"Gupta","year":"2017","journal-title":"Oral Dis"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101352_bib0019","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin Inhibitors: 40 Years Later, Can't Live Without \u2026","volume":"191","author":"Azzi","year":"2013","journal-title":"J Immunol"},{"issue":"11-12","key":"10.1016\/j.disamonth.2022.101352_bib0020","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1365-2036.2011.04873.x","article-title":"Systematic review: the role of tacrolimus in the management of Crohn's disease","volume":"34","author":"McSharry","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.disamonth.2022.101352_bib0021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PTT.S101233","article-title":"Tacrolimus for the management of psoriasis: clinical utility and place in therapy","volume":"6","author":"Malecic","year":"2016","journal-title":"Psoriasis Targets Ther"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/pde.12367","article-title":"Retrospective review of relapse after systemic cyclosporine in children with atopic dermatitis","volume":"32","author":"Sibbald","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens&ndash;Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0024","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0961203309350320","article-title":"Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice","volume":"19","author":"Ogawa","year":"2010","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101352_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40272-013-0013-9","article-title":"Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations","volume":"15","author":"Carr","year":"2013","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.disamonth.2022.101352_bib0026","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5114\/pdia.2013.35619","article-title":"Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use","volume":"3","author":"Gutfreund","year":"2013","journal-title":"Adv Dermatology Allergol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0027","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40257-013-0020-1","article-title":"Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice","volume":"14","author":"Siegfried","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0028","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-051X.2007.01191.x","article-title":"Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus","volume":"35","author":"Corrocher","year":"2008","journal-title":"J Clin Periodontol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0029","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ijd.12887","article-title":"Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial","volume":"55","author":"Vohra","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0030","article-title":"The efficacy of tacrolimus 0.1% ointment in elderly patients with oral lichen planus","author":"Yang","year":"2010","journal-title":"Chin J Geriatr Dent"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101352_bib0031","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/odi.12653","article-title":"Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial","volume":"23","author":"Siponen","year":"2017","journal-title":"Oral Dis"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0032","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tripleo.2007.07.029","article-title":"A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus","volume":"105","author":"Radfar","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodontology"},{"key":"10.1016\/j.disamonth.2022.101352_bib0033","article-title":"A randomized clinical trial of topical dexamethasone vs. cyclosporine treatment for oral lichen planus","author":"Georgaki","year":"2020","journal-title":"Med Oral Patol Oral y Cir Bucal"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101352_bib0034","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1600-0714.2011.01029.x","article-title":"Biologics, an alternative therapeutic approach for oral lichen planus","volume":"40","author":"Zhang","year":"2011","journal-title":"J Oral Pathol Med"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101352_bib0035","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1600-0714.2008.00693.x","article-title":"Off-label use of biologicals in the management of inflammatory oral mucosal disease","volume":"37","author":"ID","year":"2008","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0036","first-page":"24","article-title":"Biologic agents and oral diseases \u2013 an update on clinical applications","volume":"21","author":"Georgakopoulou","year":"2013","journal-title":"Acta Dermatovenerol Croat"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0037","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: current biologic agents and future prospects in RA","volume":"9","author":"Choy","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0038","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","article-title":"Lichen planus\u2013like eruptions: An emerging side effect of tumor necrosis factor-\u03b1 antagonists","volume":"61","author":"Asarch","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101352_bib0039","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2133.2005.06914.x","article-title":"Infliximab treatment for severe orogenital ulceration in Behcet's disease","volume":"153","author":"Connolly","year":"2005","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.142.2.151","article-title":"Treatment of generalized lichen planus with alefacept","volume":"142","author":"Fivenson","year":"2006","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101352_bib0041","first-page":"379","article-title":"Alefacept for erosive lichen planus: a case series","volume":"7","author":"Chang","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101352_bib0042","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/archderm.139.10.1259","article-title":"Recurrent aphthous stomatitis treated with etanercept","volume":"139","author":"Recalcitrant","year":"2003","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101352_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares","year":"2006","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0044","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","article-title":"Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor \u03b1 antagonist etanercept","volume":"46","author":"Sacher","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0045","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101352_bib0046","first-page":"940","article-title":"Successful treatment of pemphigus vulgaris with etanercept in four patients","volume":"8","author":"Shetty","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0047","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00128071-200708020-00010","article-title":"Etanercept for the Management of Oral Lichen Planus","volume":"8","author":"Yarom","year":"2007","journal-title":"Am J Clin Dermatol"},{"issue":"10083","key":"10.1016\/j.disamonth.2022.101352_bib0048","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0049","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sj\u00f6gren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101352_bib0050","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101352_bib0051","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101352_bib0052","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional b cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101352_bib0053","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101352_bib0054","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0055","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0056","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sj\u00f6gren's syndrome: follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0057","doi-asserted-by":"crossref","first-page":"kev257","DOI":"10.1093\/rheumatology\/kev257","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren's syndrome: the BELISS open-label phase II study","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0058","first-page":"129","article-title":"Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab","volume":"76","author":"Vujevich","year":"2005","journal-title":"Cutis"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101352_bib0059","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1600-0714.2009.00796.x","article-title":"The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial","volume":"38","author":"Xiong","year":"2009","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/antiox10020261","article-title":"Nutraceuticals against oxidative stress in autoimmune disorders","volume":"10","author":"Mannucci","year":"2021","journal-title":"Antioxidants"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0061","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2133.2007.08370.x","article-title":"The efficacy of aloe vera gel in the treatment of oral lichen planus: a randomized controlled trial","volume":"158","author":"Choonhakarn","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0062","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jop.12130","article-title":"Clinical efficacy of new aloe vera- and myrrh-based oral mucoadhesive gels in the management of minor recurrent aphthous stomatitis: a randomized, double-blind, vehicle-controlled study","volume":"43","author":"Mansour","year":"2014","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.disamonth.2022.101352_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.hermed.2020.100336","article-title":"New concentration of curcumin orabase in recurrent aphthous stomatitis: a randomized, controlled clinical trial","volume":"22","author":"Kia","year":"2020","journal-title":"J Herb Med"},{"key":"10.1016\/j.disamonth.2022.101352_bib0064","article-title":"Novel material in the treatment of minor oral recurrent aphthous stomatitis","author":"Halim","year":"2013","journal-title":"Int Med J"},{"key":"10.1016\/j.disamonth.2022.101352_bib0065","first-page":"1","article-title":"Efficacy of curcumin for recurrent aphthous stomatitis: a systematic review","author":"Al-Maweri","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101352_bib0066","first-page":"789","article-title":"Comparative efficacy of topical curcumin and triamcinolone for oral lichen planus: a randomized, controlled clinical trial","volume":"12","author":"Kia","year":"2015","journal-title":"J Dent (Tehran)"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0067","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/09546634.2018.1543849","article-title":"Clinical safety and efficacy of curcumin use for oral lichen planus: a systematic review","volume":"30","author":"Lv","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0068","first-page":"449","article-title":"To evaluate efficiency of curcumin and honey in patients with recurrent aphthous stomatitis: a randomized clinical controlled trial","volume":"6","author":"Pandharipande","year":"2019","journal-title":"Int J Res Rev"},{"key":"10.1016\/j.disamonth.2022.101352_bib0069","first-page":"48","article-title":"Comparison the efficacy of honey mouthwash with hydrogen peroxide mouthwash on oral lesions healing in patients with Pemphigus .Abstract Background Pemphigus is a rare and potentially life-threatening disease. It produces blisters in the skin and mucous m","volume":"21","author":"Oskuee","year":"2012","journal-title":"Adv Nurs Midwifery"},{"issue":"76","key":"10.1016\/j.disamonth.2022.101352_bib0070","first-page":"151","article-title":"Effect of cedar honey in the treatment of oral lichen planus","volume":"26","author":"Sanatkhani","year":"2014","journal-title":"Iran J Otorhinolaryngol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0071","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00784-009-0267-3","article-title":"The efficacy of a paste containing Myrtus communis (Myrtle) in the management of recurrent aphthous stomatitis: a randomized controlled trial","volume":"14","author":"Babaee","year":"2010","journal-title":"Clin Oral Investig"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0072","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF02850010","article-title":"Safety and efficacy ofEupatorium laevigatum paste as therapy for buccal aphthae: Randomized, double-blind comparison with triamcinolone 0.1% orabase","volume":"17","author":"Filho","year":"2000","journal-title":"Adv Ther"},{"key":"10.1016\/j.disamonth.2022.101352_bib0073","doi-asserted-by":"crossref","DOI":"10.4317\/jced.52665","article-title":"The effect of diode laser and topical steroid on serum level of TNF-alpha in oral lichen planus patients","author":"Othman","year":"2016","journal-title":"J Clin Exp Dent"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0074","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3889\/oamjms.2015.072","article-title":"A comparative evaluation of low-level laser and topical steroid therapies for the treatment of erosive-atrophic lichen planus","volume":"3","author":"Elshenawy","year":"2015","journal-title":"Open Access Maced J Med Sci"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0075","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10103-017-2233-7","article-title":"Efficacy of low-level laser therapy in management of symptomatic oral lichen planus: a systematic review","volume":"32","author":"Al-Maweri","year":"2017","journal-title":"Lasers Med Sci"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101352_bib0076","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10103-012-1101-8","article-title":"Low-level laser therapy on the treatment of oral and cutaneous pemphigus vulgaris: case report","volume":"27","author":"Minicucci","year":"2012","journal-title":"Lasers Med Sci"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101352_bib0077","doi-asserted-by":"crossref","first-page":"177","DOI":"10.15171\/jlms.2017.32","article-title":"The effect of low level laser therapy on pemphigus vulgaris lesions: a pilot study","volume":"8","author":"Yousefi","year":"2017","journal-title":"J Lasers Med Sci"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101352_bib0078","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1902\/jop.2010.100095","article-title":"Low-level laser therapy in the treatment of mucous membrane pemphigoid: a promising procedure","volume":"81","author":"Yilmaz","year":"2010","journal-title":"J Periodontol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.oooo.2019.06.056","article-title":"Treatment of mucous membrane pemphigoid with low-level laser therapy","author":"Gomes","year":"2020","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0080","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10103-012-1137-9","article-title":"Low-level laser therapy for oral mucous membrane pemphigoid","volume":"27","author":"Cafaro","year":"2012","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.disamonth.2022.101352_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2021.102318","article-title":"Application of photodynamic therapy in immune-related diseases","volume":"34","author":"Yang","year":"2021","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.disamonth.2022.101352_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2020.101677","article-title":"Could photodynamic therapy be utilized as a treatment modality for oral lichen planus?","volume":"30","author":"Saleh","year":"2020","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.disamonth.2022.101352_bib0083","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pdpdt.2018.11.009","article-title":"A clinical evaluation of efficacy of photodynamic therapy in treatment of reticular oral lichen planus: A case series","volume":"25","author":"Sulewska","year":"2019","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101352_bib0084","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-3083.2008.02976.x","article-title":"Photodynamic therapy: a useful adjunct therapy for recalcitrant ulceration in pemphigus vulgaris","volume":"23","author":"Bakos","year":"2009","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101352_bib0085","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1067\/mjd.2002.124802","article-title":"Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease)","volume":"47","author":"Ruiz-Rodrigueza","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0086","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5021\/ad.2015.27.2.222","article-title":"Successful treatment of hailey-hailey disease with aminolevulinic acid photodynamic therapy","volume":"27","author":"Yan","year":"2015","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0087","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pdpdt.2017.05.014","article-title":"Pemphigus vulgaris induced by 5-aminolaevulinic acid-based photodynamic therapy","volume":"19","author":"Zhou","year":"2017","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101352_bib0088","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1600-0781.2011.00609.x","article-title":"Localized bullous pemphigoid induced by photodynamic therapy","volume":"27","author":"Rakvit","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101352_bib0089","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/ijd.13387","article-title":"Photodynamic therapy-triggered bullous pemphigoid","volume":"56","author":"Kluger","year":"2017","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101352_bib0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.disamonth.2022.101352_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.disamonth.2022.101352_bib0092","doi-asserted-by":"crossref","DOI":"10.3410\/M4-5","article-title":"Kinase inhibitors in the treatment of immune-mediated disease","volume":"4","author":"Kontzias","year":"2012","journal-title":"F1000 Med Rep"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0093","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen A","year":"2019","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0094","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101352_bib0095","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"10.1016\/j.disamonth.2022.101352_bib0096","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"10188","key":"10.1016\/j.disamonth.2022.101352_bib0097","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0098","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical <scp>J<\/scp>anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0099","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK<\/scp>) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"10143","key":"10.1016\/j.disamonth.2022.101352_bib0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.disamonth.2022.101352_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine Kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.disamonth.2022.101352_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00078","article-title":"Targeting syk in autoimmune rheumatic diseases","volume":"7","author":"Deng","year":"2016","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101352_bib0103","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0104","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1093\/rheumatology\/keaa732","article-title":"Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study","volume":"60","author":"Tanaka","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101352_bib0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*","volume":"185","author":"Murrell","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0106","doi-asserted-by":"crossref","first-page":"e00370","DOI":"10.1002\/prp2.370","article-title":"Cenerimod, a novel selective S1P 1 receptor modulator with unique signaling properties","volume":"5","author":"Piali","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0107","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P 1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0108","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13075-021-02673-x","article-title":"Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sj\u00f6gren's syndrome","volume":"23","author":"Gerossier","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"9959","key":"10.1016\/j.disamonth.2022.101352_bib0109","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101352_bib0110","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1016\/j.sjbs.2021.07.029","article-title":"Assessing the effect of human dental pulp mesenchymal stem cell secretome on human oral, breast, and melanoma cancer cell lines","volume":"28","author":"Raj","year":"2021","journal-title":"Saudi J Biol Sci"},{"issue":"18","key":"10.1016\/j.disamonth.2022.101352_bib0111","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.3390\/molecules26185683","article-title":"The growth factors and cytokines of dental pulp mesenchymal stem cell secretome may potentially aid in oral cancer proliferation","volume":"26","author":"Raj","year":"2021","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101352_bib0112","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/coatings11091035","article-title":"Role of stem cells in augmenting dental implant osseointegration: a systematic review","volume":"11","author":"Sayed","year":"2021","journal-title":"Coatings"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101352_bib0113","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/jpm11050430","article-title":"Viability of quercetin-induced dental pulp stem cells in forming living cellular constructs for soft tissue augmentation","volume":"11","author":"Fageeh","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0114","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.disamonth.2022.101352_bib0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01191","article-title":"Immunomodulation by Mesenchymal Stem Cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs","volume":"10","author":"Weiss","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101352_bib0116","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/art.24405","article-title":"Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells","volume":"60","author":"Gonz\u00e1lez","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101352_bib0117","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2249.2010.04158.x","article-title":"Allogeneic mesenchymal stem cells do not protect NZB\u00a0\u00d7\u00a0NZW F1 mice from developing lupus disease","volume":"161","author":"Youd","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101352_bib0118","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/stem.68","article-title":"Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans","volume":"27","author":"Sun","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.disamonth.2022.101352_bib0119","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5114\/ceji.2017.70974","article-title":"Interference RNA in immune-mediated oral diseases \u2013 minireview","volume":"3","author":"Dhanapal","year":"2017","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.disamonth.2022.101352_sbref0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-1-4939-8802-0_13","article-title":"RNA Interference Ex Vivo","volume":"1868","author":"Liu","year":"2018","journal-title":"In. Methods Mol Biol"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502922000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502922000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T01:03:29Z","timestamp":1757898209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502922000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0011502922000360"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2022.101352","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancement in therapeutic strategies for immune-mediated oral diseases","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2022.101352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101352"}}